← Back to Search

Light Exposure to Prevent Frailty in Prostate Cancer Patients

Phase < 1
Waitlist Available
Led By William Dale
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
A life expectancy of 6 months or longer.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Study Summary

This trial is studying if light exposure can help prevent frailty in older prostate cancer patients on hormone therapy.

Who is the study for?
This trial is for older prostate cancer patients starting hormone therapy with minimal disease burden, who can sign consent and have a life expectancy of 6 months or more. It's not for those with severe sleep disorders, eye diseases affecting light processing, psychological impairments, night shift workers, recent secondary cancers, plans to travel across time zones during treatment, uncontrolled illnesses or infections.Check my eligibility
What is being tested?
The study tests if systematic light exposure prevents frailty symptoms caused by hormone therapy in older men with prostate cancer. Frailty includes fatigue, slow walking speed, reduced activity levels, muscle loss and weakness. The trial involves questionnaires and actigraphy (movement monitoring) to assess the effects.See study design
What are the potential side effects?
Since this trial focuses on light exposure rather than medication or invasive procedures, side effects are expected to be minimal. However specific side effects are not detailed in the provided information.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are expected to live for at least 6 more months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frailty development in older PC patients following prostate anti-androgen therapies initiation
Physical performance in older prostate cancer (PC) patients following prostate anti-androgen therapies initiation
Secondary outcome measures
Activity level
Fatigue level
Hand-grip strength measured using hand-held dynamometer
+2 more
Other outcome measures
Collecting and storing clinically-usable bio-measures

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm II (DWL)Experimental Treatment3 Interventions
Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo DWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
Group II: Arm I (BWL)Experimental Treatment3 Interventions
Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo BWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Actigraph
2005
N/A
~1440

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,603 Previous Clinical Trials
40,913,242 Total Patients Enrolled
559 Trials studying Prostate Cancer
507,021 Patients Enrolled for Prostate Cancer
City of Hope Medical CenterLead Sponsor
558 Previous Clinical Trials
1,917,418 Total Patients Enrolled
13 Trials studying Prostate Cancer
5,580 Patients Enrolled for Prostate Cancer
William DalePrincipal InvestigatorCity of Hope Medical Center
3 Previous Clinical Trials
650 Total Patients Enrolled
2 Trials studying Prostate Cancer
434 Patients Enrolled for Prostate Cancer

Media Library

Systemic Light Exposure Clinical Trial Eligibility Overview. Trial Name: NCT03661437 — Phase < 1
Prostate Cancer Research Study Groups: Arm I (BWL), Arm II (DWL)
Prostate Cancer Clinical Trial 2023: Systemic Light Exposure Highlights & Side Effects. Trial Name: NCT03661437 — Phase < 1
Systemic Light Exposure 2023 Treatment Timeline for Medical Study. Trial Name: NCT03661437 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies available for individuals to participate in this research?

"This investigation, which was initially published on September 24th 2018 and last modified on May 10th 2022 is no longer accepting patients. However, there are currently 1466 other trials in need of participants."

Answered by AI

What are the chief goals of this experiment?

"This medical trial, conducted over a 6-month period, aims to assess frailty in elderly prostate cancer patients post initiation of anti-androgen therapy. Secondary objectives include evaluating fatigue levels via the FACIT-Fatigue scale, hand grip strength with a handheld dynamometer, and IADLs with a repeated measures mixed linear model."

Answered by AI
~5 spots leftby Mar 2025